Kimberly M. Kelly, PhD, MS

Professor

Organization:

West Virginia University School of Pharmacy

Department:

Pharmaceutical Systems & Policy

Classification:

Faculty

Member

Organization:

West Virginia University WVU Cancer Institute

Department:

WVU Cancer Institute Research Programs

Classification:

Faculty

• PhD, Psychology, Rutgers, The State University of New Jersey, 2000
• MS, Genetic Counseling, Indiana University, School of Medicine, Indianapolis, IN, 2002

Ten Most Recent:

The Impact of Diffuse Large B-Cell Lymphoma (DLBCL) on Mammography and Bone Density Testing in Women with DLBCL as Compared to Women without Cancer. Garg, R., Sambamoorthi, U., Tan, X., Basu, S.K., Haggerty, T., Kelly, K.M.* Journal of Primary Prevention. 2021;42(2):143-16. https://link.springer.com/article/10.1007%2Fs10935-021-00621-8

SCAN! A pharmacy-based, sun safety feasibility study. Kelly, K.M.*, Dhumal, T., Scott, V., Mbous, Y., Chotiner, M., Powers, R., Whetsel, T., Safarudin, F., Cornelius, P., Garofoli, G.  Journal of the American Pharmacists Association. 2021; 61(1): e69-e79. https://www.sciencedirect.com/science/article/pii/S154431912030488X?casa_token=QItjzZUxbisAAAAA:WU-O4tL6N0Jyqx14TYVeONwsg1AnKW_gYVQLdWe0j9XqxjnkApR1jXYi7ihqvmT00td3ojV6LI0

Factors associated with immune checkpoint inhibitor use among older adults with late-stage melanoma: A population-based study. Rai, P., Shen, C., Kolodney, J., Kelly, K.M., Scott, V.G., Sambamoorthi, U. Medicine. 2021; 100(7): e24782.​  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899862/

Immune checkpoint inhibitor use, multimorbidity and healthcare expenditures among older adults with late-stage melanoma. Rai, P., Shen, C., Kolodney, J., Kelly, K.M., Scott, V.G., Sambamoorthi, U. Immunotherapy. 2021; 13(2):103-112. doi: 10.2217/imt-2020-0152.​  https://www.futuremedicine.com/doi/10.2217/imt-2020-0152?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed

Prevalence and risk factors for multimorbidity in older US patients with late-stage melanoma. Rai, P., Shen, C., Kolodney, J., Kelly, K.M., Scott, V.G., Sambamoorthi, U. Journal of Geriatric Oncology. 2021;12(3):388-393.  https://www.geriatriconcology.net/article/S1879-4068(20)30446-X/fulltext

A systematic review and meta-analysis of physical activity interventions among colorectal cancer survivors. Mbous, Y.P., Shah, J., Kelly, K.M.* Translational Behavioral Medicine (Diamond Anniversary special issue); 2020; 10(5):1134-1143. systematic review and meta-analysis of physical activity interventions among colorectal cancer survivors | Translational Behavioral Medicine | Oxford Academic (oup.com)

A systematic review of interventions using health behavioral theories to improve medication adherence among patients with hypertension. Nili, M., Mohamed, R., Kelly, K.M.* Translational Behavioral Medicine (Diamond Anniversary special issue). 2020; 10(5):1177-1186. systematic review of interventions using health behavioral theories to improve medication adherence among patients with hypertension | Translational Behavioral Medicine | Oxford Academic (oup.com)

Interest in tobacco cessation interventions among pharmacists and student pharmacists in a high prevalence state. Rai, P., Agarwal, P., Scott, V.G., Tworek, C., Elswick, B.M., Kelly, K.M.* Addictive Disorders & Their Treatment. 2020; 19(2): 108-117.  Interest in Tobacco and Smoking Cessation Interventions Amon... : Addictive Disorders & Their Treatment (lww.com)

Feasibility and acceptability of safety screening among patients receiving addiction treatment. Stover, A.N., Rockett, I.R.H., Smith, G.S., LeMasters, T., Scott, V.G., Kelly, K.M., Winstanley, E.L. Journal of Substance Abuse Treatment. 2020:117:108092.  https://www.sciencedirect.com/science/article/abs/pii/S0740547220303482

Insure Me Cancer Free: An intervention utilizing a Dynamic Communication Model. Kelly, K.M.*, Dolly, B., Kennedy, S., Atkins, E., Coon, M., King, K., Mbous, Y., Rouse, S. Health Behavior Research (Health Equity special issue) 2019; 2(1): 1-13.

Dr. Kimberly Kelly is a Professor in the Department of Pharmaceutical Systems and Policy in the School of Pharmacy and the West Virginia University Cancer Institute. She received her MS (1998) and PhD (2000) in social and health psychology from Rutgers University, her MS (2002) in genetic counseling from Indiana University, and completed a post-doctoral fellowship in Cancer Control and Behavioral Science at the University of Kentucky (2002-2004). She oversees Admissions for the Health Services and Outcomes Research PhD Program. Her teaching includes Health Survey Research Methods and Social and Behavioral Theory in the PhD program and Population Health and Policy in the PharmD curriculum. Her research relies on behavioral theory from psychology (health, social, cognitive), as well as communication and information sciences. She mixes qualitative and quantitative methods, utilizing clinic-based and community-based approaches. Dr. Kelly conducts research on populations at elevated risk for cancer and seeks ways to help reduce that risk through behavioral intervention strategies.

Dr. Kimberly Kelly is a Professor in the Department of Pharmaceutical Systems and Policy in the School of Pharmacy and the West Virginia University Cancer Institute. She received her MS (1998) and PhD (2000) in social and health psychology from Rutgers University, her MS (2002) in genetic counseling from Indiana University, and completed a post-doctoral fellowship in Cancer Control and Behavioral Science at the University of Kentucky (2002-2004). She oversees Admissions for the Health Services and Outcomes Research PhD Program. Her teaching includes Health Survey Research Methods and Social and Behavioral Theory in the PhD program and Population Health and Policy in the PharmD curriculum. Her research relies on behavioral theory from psychology (health, social, cognitive), as well as communication and information sciences. She mixes qualitative and quantitative methods, utilizing clinic-based and community-based approaches. Dr. Kelly conducts research on populations at elevated risk for cancer and seeks ways to help reduce that risk through behavioral intervention strategies.

Research

Three overlapping themes emerge from Dr. Kelly’s research: (1) cancer risk perception/communication, (2) health behavior (e.g., cancer screening, genetic testing), and (3) elevated risk populations (e.g., Appalachians, those with a family history of cancer). Most of her research has focused on how risk is communicated in the context of cancer genetic counseling and how risk perceptions differ from objective estimates of risk. Her recent funded work examines the role of risk communication in cancer screening and cancer treatment. Through her research, Dr. Kelly hopes to understand how best to enhance appropriate decision-making about health behaviors in elevated risk populations to accomplish optimal health outcomes.

Cancer Institute Research Program

Three overlapping themes emerge from Dr. Kelly’s research: (1) cancer risk perception/communication, (2) health behavior (e.g., cancer screening, genetic testing), and (3) elevated risk populations (e.g., Appalachians, those with a family history of cancer). Most of her research has focused on how risk is communicated in the context of cancer genetic counseling and how risk perceptions differ from objective estimates of risk. Her recent funded work examines the role of risk communication in cancer screening and cancer treatment. Through her research, Dr. Kelly hopes to understand how best to enhance appropriate decision-making about health behaviors in elevated risk populations to accomplish optimal health outcomes.